---
title: "Telix Pharmaceuticals Q2 Revenue Climbs Boosted By Precision Medicine Business"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293292304.md"
description: "Telix Pharmaceuticals reported Q2 fiscal 2026 revenue of $247 million, up from $204 million year-over-year, driven by precision medicine sales reaching $202 million. The company raised its full-year fiscal 2026 revenue guidance to over $1 billion, with expected revenue between $950-$970 million plus $40 million in other income. R&D expenditure is now projected at $230-$270 million."
datetime: "2026-07-21T05:45:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293292304.md)
  - [en](https://longbridge.com/en/news/293292304.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293292304.md)
generator: "portal-rs"
---

# Telix Pharmaceuticals Q2 Revenue Climbs Boosted By Precision Medicine Business

Add  as your preferred news source on Google

 Add Now

Telix Pharmaceuticals Limited (TLX), a radiopharmaceutical company, reported a rise in revenue for the second quarter, helped by the increased revenue from the precision medicine business. 

For the second quarter of fiscal 2026, the company posted revenue of $247 million, higher than $204 million in the same period last year. Revenue from the precision medicine business stood at $202 million as against the prior year's $155 million.

Looking ahead, for fiscal 2026, the company expects revenue and other income of over $1 billion, with revenue tracking in line with the upper end of fiscal 2026 guidance of $950 million to $970 million, and $40 million non-refundable other income from Regeneron. 

For fiscal 2026, Telix now projects research and development expenditure of $230 million to $270 million, higher than the earlier guidance of $200 million to $240 million.

For fiscal 2025, the company had posted revenue of $803.8 million, with an investment of $157.1 million in research and development. 

For comments and feedback contact: editorial@rttnews.com

Business News

### Related Stocks

- [TLX.AU](https://longbridge.com/en/quote/TLX.AU.md)
- [TLX.US](https://longbridge.com/en/quote/TLX.US.md)
- [REGN.US](https://longbridge.com/en/quote/REGN.US.md)

## Related News & Research

- [Telix Appoints David Gill as Chair | TLX Stock News](https://longbridge.com/en/news/297567288.md)
- [Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway | TLX Stock News](https://longbridge.com/en/news/297704266.md)
- [REG - Barclays PLC Adv Medical Solutns. - Form 8.3 ADVANCED MEDICAL SOLUTIONS GROUP PLC](https://longbridge.com/en/news/298035944.md)
- [REG - American Century Inv Spire Healthcare Grp - Form 8.3 - Spire Healthcare Group PLC](https://longbridge.com/en/news/298045178.md)
- [REG - BlackRock Group Adv Medical Solutns. - Form 8.3 - Advanced Medical Solutions Group plc](https://longbridge.com/en/news/297929095.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**